Support Alert

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a change to the Patient Information Leaflet, concerning possible side effects for Rifadin (rifampicin) 150mg Capsules, has not been implemented by the required timeline.

Some of our content, including support alerts, is only available to RPS members. 

Log in

Find out more about membership of the Society